title: Albendazole treatment of children with ascariasis enhances the vibriocidal antibody response to the live attenuated oral cholera vaccine CVD 103-HgR.
abstract: Because concurrent infections with geohelminth parasites might impair the immune response to oral vaccines, we studied the vibriocidal antibody response to the oral cholera vaccine CVD 103-HgR in children infected with Ascaris lumbricoides and investigated the effect of albendazole pretreatment on the postvaccination response. Children with ascariasis were randomized to receive either 2 sequential doses of 400 mg of albendazole or placebo. After the second dose, CVD 103-HgR was given, and serum vibriocidal antibody levels were measured before and 10 days after vaccination. Postvaccination rates of seroconversion were greater in the treatment group that received albendazole (P=.06). Significantly greater rates of seroconversion and geometric mean titer were observed in the albendazole group in subjects with non-O ABO blood groups. A significant association was observed between vibriocidal seroconversion rates and treatment group, suggesting that A. lumbricoides infections impair the immune response to oral cholera vaccine, particularly in subjects of non-O blood groups.
authors.affiliation: Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892-0425, USA. pc102d@hotmail.com
authors.forename: P J
authors.initials: PJ
authors.lastname: Cooper
authors.forename: M E
authors.initials: ME
authors.lastname: Chico
authors.forename: G
authors.initials: G
authors.lastname: Losonsky
authors.forename: C
authors.initials: C
authors.lastname: Sandoval
authors.forename: I
authors.initials: I
authors.lastname: Espinel
authors.forename: R
authors.initials: R
authors.lastname: Sridhara
authors.forename: M
authors.initials: M
authors.lastname: Aguilar
authors.forename: A
authors.initials: A
authors.lastname: Guevara
authors.forename: R H
authors.initials: RH
authors.lastname: Guderian
authors.forename: M M
authors.initials: MM
authors.lastname: Levine
authors.forename: G E
authors.initials: GE
authors.lastname: Griffin
authors.forename: T B
authors.initials: TB
authors.lastname: Nutman
mesh_terms: D000293:Adolescent; D015766:Albendazole / Q000627:therapeutic use*; D000818:Animals; D000871:Anthelmintics / Q000627:therapeutic use*; D000907:Antibodies, Bacterial / Q000097:blood*; D000917:Antibody Formation; D001196:Ascariasis / Q000188:drug therapy* / Q000276:immunology*; D017164:Ascaris lumbricoides / Q000187:drug effects; D001428:Bacterial Vaccines / Q000276:immunology*; D001789:Blood Group Antigens / Q000276:immunology; D002648:Child; D022121:Cholera Vaccines / Q000276:immunology*; D004347:Drug Interactions; D004484:Ecuador; D005260:Female; D006801:Humans; D008297:Male; D014258:Trichuris / Q000187:drug effects; D014613:Vaccines, Attenuated / Q000276:immunology*
chemical_list: D000871:Anthelmintics; D000907:Antibodies, Bacterial; D001428:Bacterial Vaccines; D001789:Blood Group Antigens; D022121:Cholera Vaccines; D014613:Vaccines, Attenuated; C414990:cholera vaccine CVD 103-HgR; D015766:Albendazole